Phase 2 N=415 Tolperisone in Acute Muscle Spasm of the Back
Back Pain · Acute Pain · Back Spasm Upper Back
Primary: Mean Effect Size in Subjected-Rated Pain — -4.2; -4.0; -3.7; -4.4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study
Muscle Cramps · Cirrhosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Headache) — 3 participants
Phase 3 N=180 Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin
Neck Pain · Back Pain · Spasm
Primary: Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment — 20.0; 28.9; 60.0; 46.7 percentage of participants — p=0.6179
Phase 2 N=4 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
N/A N=40 Beneficial Effects of Magnesium Supplementation On Idiopathic Muscle Cramps
Muscle Cramp
Primary: Change in Frequency of Leg Cramps — .99; .53 Cramps per week
N/A N=33 The Effects of Spasticity on Glucose Metabolism in Individuals With Spinal Cord Injury
Spinal Cord Injuries
Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006
Phase 4 N=49 The Muscle Relaxation-study
Cholecystectomy, Laparoscopic
Primary: The Percentage of Patients With Optimal Surgical Space Conditions ( 1 at a 4-step Scale) Assessed at the Time During Surgery, When View Was Less — 28; 4 percentage of…
Phase 4 N=240 Orphenadrine and Methocarbamol for LBP
Low Back Pain
Primary: Functional Impairment as Measured on the Roland Morris Disability Questionnaire — 10.9; 9.4; 8.1 units on a scale
N/A N=18 Spinal Cord Stimulation to Augment Activity Based Therapy
Transcutaneous Spinal Stimulation · Walking · Spasticity
Primary: Change in Walking Function - 10m Walk Walking Speed (m/s) — 0.06; 0.16 speed difference in meters per second
Phase 4 N=320 Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain
Low Back Pain
Primary: Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire (RMDQ) — 10.1; 11.2; 10.6; 11.1 units on a scale
Phase 3 N=323 A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
Multiple Sclerosis · Spasticity, Muscle
Primary: Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS Results — 276 Participants
N/A N=40 Investigating the Effects of a Spinal Mobilisation Intervention in People With Lower Back Pain
Lower Back Pain
Primary: Intervention Erector Spinae Stiffness Change — -10.959 Newton metres (Nm) — p=<0.05
Phase 2 N=142 Study of SPARC1103 in Subjects With Spasticity
Spasticity
Primary: Least Square Mean Difference (Placebo Versus Each SPARC1103 Dose) in Change From Baseline in Modified Ashworth Score — 0.33; 0.03 score on a scale
N/A N=57 Effect of Theraworx/[pH]Uel on Night-time Leg Cramps and Spasm Symptoms
Leg Cramp, Nocturnal
Primary: Change in Restless Legs Syndrome Quality of Life Instrument (RLSQoL) Over 4 Weeks — 78.92; 80.75; 77.75; 83.16 units on a scale
Phase 3 N=840 Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
Lower Back Pain
Primary: Subject Rated Change Relief From Starting Backache of Pain on a 100-point Visual Analog Scale — 16.4; 15.5; 15.2 mm
Phase 4 N=23 Mexiletine for the Treatment of Muscle Cramps in ALS
Muscle Cramps in Amyotrophic Lateral Sclerosis
Primary: Daily Muscle Cramps — 6.1; 4.7; 4.9; 2.5 Cramps per 24 hours
Phase 3 N=840 A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
Lower Back Pain
Primary: Subject Rating of Pain on a 100-point Visual Analog Scale (VAS) — 27.5; 28; 28.6 mm
N/A N=16 Functional Change With MMS
Muscle Weakness
Primary: Change in Body Satisfaction Questionnaire From Baseline to 1-month Post-Treatment Follow-up Visit — 8.6 units on a scale
N/A N=20 MS Spinal Mobilisation Study
Multiple Sclerosis
Primary: Participant Muscle Stiffness Measure — 350.83; 240.07 Newton-metres
N/A N=17 Palliative Strategies in Spinal Cord Injury (SCI)
Spinal Cord Injury
Primary: Muscle Mass Via Dual-Energy X-ray Absortiometry (DEXA)Scan Data — 6104.45; 6355.3 grams — p=.318
N/A N=79 Exploratory Efficacy Study of Guaifenesin in Upper Back Pain
Upper Back Pain
Primary: Mean Change From Baseline of Both AM and PM Spasm Assessment Scores — 1.66; 1.87; 1.91; 1.54 Score on a Scale — p=0.68
N/A N=231 Evaluation of a Spasticity Management Program for People With Multiple Sclerosis
Multiple Sclerosis
Primary: Impact of Spasticity, Measured by the Multiple Sclerosis Spasticity Scale-88 — -16.11; -15.83 units on a scale
N/A N=30 Muscle Fatigue and Scapular Sensorimotor System
Muscle; Fatigue
Primary: Change From Baseline in Scapular Proprioception — -0.48; -0.19; -0.37; -0.32 centimeters — p=0.227
N/A N=20 Cramer Sports Motion Tape and Low Back Pain EMG
Low Back Pain
Primary: Percent of Maximal Voluntary Isometric Contraction (%MVIC) — 226.41; 250.51; 162.47; 205.82 % of Max Voluntary Isometric Contraction
Phase 3 N=289 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Post-stroke Spasticity of the Lower Limb
Primary: Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4 — 2.8; 2.8; -0.4; -0.4 Units on a scale — p=0.777
Phase 2 N=11 TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
Amyotrophic Lateral Sclerosis · Muscle Cramp
Primary: Visual Analog Scale (MCS-VAS) Score — 2.07; 1.7 score on a scale
N/A N=60 Assesment of Post-stroke Elbow Flexor Spasticity in Different Forearm Positions
Post-stroke Elbow Spasticity
Primary: Dynamic Component of Spasticity (Spasticity Angle) — 70; 60; 57.5 degree — p=<0.001
N/A N=7 Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS
Multiple Sclerosis
Primary: Expanded Disability Status Score — 6.8 score on a scale
Phase 1 N=23 Autologous Muscle Derived Cells for Underactive Bladder
Urinary Retention · Urinary Incontinence
Primary: Number of Participants With Study-related Adverse Events at 6 Months — 2; 1; 1; 1 participants
Phase 3 N=536 A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Multiple Sclerosis · Spasticity, Muscle
Primary: Change From Baseline in Total Numeric-transformed Modified Ashworth Scale Score of the Most Affected Limb (TNmAS-MAL) — -1.7; -2.0; -1.4 units on a scale